BOLD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. BOLD has a great financial health rating, but its profitability evaluates not so good. BOLD does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

BOLD had negative earnings in the past year.
BOLD had a negative operating cash flow in the past year.

1.2 Ratios

Looking at the Return On Assets, with a value of -36.60%, BOLD is in the better half of the industry, outperforming 60.95% of the companies in the same industry.
The Return On Equity of BOLD (-56.06%) is better than 64.19% of its industry peers.

		Industry Rank	Sector Rank
ROA	-36.6%
ROE	-56.06%
ROIC	N/A

ROA(3y)-43.16%

ROA(5y)N/A

ROE(3y)-51.23%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BOLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for BOLD has been increased compared to 1 year ago.
There is no outstanding debt for BOLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

BOLD has an Altman-Z score of -2.33. This is a bad value and indicates that BOLD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.33, BOLD perfoms like the industry average, outperforming 49.52% of the companies in the same industry.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.33

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

BOLD has a Current Ratio of 10.14. This indicates that BOLD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BOLD (10.14) is better than 81.33% of its industry peers.
A Quick Ratio of 10.14 indicates that BOLD has no problem at all paying its short term obligations.
The Quick ratio of BOLD (10.14) is better than 81.33% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.14
Quick Ratio	10.14

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BOLD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -484.97%.

EPS 1Y (TTM)-484.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.22%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

BOLD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y82.65%

EPS Next 2Y36.1%

EPS Next 3Y24.46%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLD. No positive earnings are expected for the next year.